CS First Boston Cuts Genentech Rating

Analyst Mark Augustine doesn't think cancer treatment Avastin will win approval in 2004 or anytime soon

CS First Boston downgraded Genentech (DNA ) to underperform from neutral.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.